Top

Current Hypertension Reports

Published in:

01-11-2018 | Hypertension and Metabolic Syndrome (J Sperati, Section Editor)

Adipose Tissue and Modulation of Hypertension

Authors: Eashita Das, Joon Ho Moon, Ju Hee Lee, Nikita Thakkar, Zdenka Pausova, Hoon-Ki Sung

Published in: Current Hypertension Reports | Issue 11/2018

Abstract

Purpose of Review

Obesity is a major risk factor for the development of hypertension (HTN), a leading cause of cardiovascular morbidity and mortality. Growing body of research suggests that adipose tissue function is directly associated with the pathogenesis of obesity-related HTN. In this review, we will discuss recent research on the role of adipose tissue in blood pressure (BP) regulation and activation of brown adipose tissue (BAT) as a potentially new therapeutic means for obesity-related HTN.

Recent Findings

Adipose tissue provides mechanical protection of the blood vessels and plays a role in regulation of vascular tone. Exercise and fasting activate BAT and induce browning of white adipose tissue (WAT). BAT-secreted FGF21 lowers BP and protects against HTN. Browning of perivascular WAT improves HTN.

Summary

New insights on WAT browning and BAT activation can open new avenues of potential therapeutic interventions to treat obesity-related HTN.

Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665–712. https://doi.org/10.1016/S0140-6736(16)31134-5.CrossRefPubMed

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23. https://doi.org/10.1016/S0140-6736(05)17741-1.CrossRef

MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.CrossRef

Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583–612.CrossRef

Richards RJ, Thakur V, Reisin E. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment. J Hum Hypertens. 1996;10(Suppl 3):S59–64.PubMed

Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens. 2006;15(2):173–8. https://doi.org/10.1097/01.mnh.0000214775.42103.a5.CrossRefPubMed

Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16(2):235–51.CrossRef

Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J 3rd. Hazards of obesity—the Framingham experience. Acta Med Scand Suppl. 1988;723:23–36.PubMed

Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8(3):270–8. https://doi.org/10.1038/oby.2000.32.CrossRef

10.

Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9.CrossRef

11.

Hruby A, Hu FB. The epidemiology of obesity: a big picture. PharmacoEconomics. 2015;33(7):673–89. https://doi.org/10.1007/s40273-014-0243-x.CrossRefPubMedPubMedCentral

12.

Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA. 2004;291(17):2107–13.CrossRef

13.

Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40(4):441–7.CrossRef

14.

Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med. 1997;337(13):869–73.CrossRef

15.

Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens. 1995;8(7):657–65.CrossRef

16.

Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetol Metab Syndr. 2014;6(1):12. https://doi.org/10.1186/1758-5996-6-12.CrossRefPubMedPubMedCentral

17.

Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48(5):787–96. https://doi.org/10.1161/01.HYP.0000242642.42177.49.CrossRefPubMed

18.

Jiang SZ, Lu W, Zong XF, Ruan HY, Liu Y. Obesity and hypertension. Exp Ther Med. 2016;12(4):2395–9. https://doi.org/10.3892/etm.2016.3667.CrossRefPubMedPubMedCentral

19.

Leggio M, Lombardi M, Caldarone E, Severi P, D'Emidio S, Armeni M, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res. 2017;40(12):947–63. https://doi.org/10.1038/hr.2017.75.CrossRefPubMed

20.

Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Unger T. Vascular remodeling in systemic hypertension. Am J Cardiol. 1993;71(17):2E–7E.CrossRef

21.

•• Kong LR, Zhou YP, Chen DR, Ruan CC, Gao PJ. Decrease of perivascular adipose tissue browning is associated with vascular dysfunction in spontaneous hypertensive rats during aging. Front Physiol. 2018;9:400. https://doi.org/10.3389/fphys.2018.00400. The study describes that perivascular adipose tissue browning is required to reduce hypertension with ageing. CrossRefPubMedPubMedCentral

22.

Almind K, Manieri M, Sivitz WI, Cinti S, Kahn CR. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc Natl Acad Sci U S A. 2007;104(7):2366–71. https://doi.org/10.1073/pnas.0610416104.CrossRefPubMedPubMedCentral

23.

Cypess AM, Kahn CR. Brown fat as a therapy for obesity and diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):143–9. https://doi.org/10.1097/MED.0b013e328337a81f.CrossRefPubMedPubMedCentral

24.

Cypess AM, Kahn CR. The role and importance of brown adipose tissue in energy homeostasis. Curr Opin Pediatr. 2010;22(4):478–84. https://doi.org/10.1097/MOP.0b013e32833a8d6e.CrossRefPubMedPubMedCentral

25.

Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab. 2013;17(1):61–72. https://doi.org/10.1016/j.cmet.2012.12.010.CrossRefPubMed

26.

Sung HK, Michael IP, Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Curr Opin Hematol. 2010;17(3):206–12. https://doi.org/10.1097/MOH.0b013e32833865e6. This study shows that intermittent fasting induces browning of adipose tissue by upregulation of VEGF. CrossRefPubMed

27.

•• Kim KH, Kim YH, Son JE, Lee JH, Kim S, Choe MS, et al. Intermittent fasting promotes adipose thermogenesis and metabolic homeostasis via VEGF-mediated alternative activation of macrophage. Cell Res. 2017;27(11):1309–26. https://doi.org/10.1038/cr.2017.126. This study shows that intermittent fasting induces browning of adipose tissue by upregulation of VEGF. CrossRefPubMedPubMedCentral

28.

Victorio JA, Fontes MT, Rossoni LV, Davel AP. Different anti-contractile function and nitric oxide production of thoracic and abdominal perivascular adipose tissues. Front Physiol. 2016;7:295. https://doi.org/10.3389/fphys.2016.00295.CrossRefPubMedPubMedCentral

29.

Brown NK, Zhou Z, Zhang J, Zeng R, Wu J, Eitzman DT, et al. Perivascular adipose tissue in vascular function and disease: a review of current research and animal models. Arterioscler Thromb Vasc Biol. 2014;34(8):1621–30. https://doi.org/10.1161/ATVBAHA.114.303029.CrossRefPubMedPubMedCentral

30.

Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, et al. Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-gamma deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation. 2012;126(9):1067–78. https://doi.org/10.1161/CIRCULATIONAHA.112.104489.CrossRefPubMedPubMedCentral

31.

Fitzgibbons TP, Kogan S, Aouadi M, Hendricks GM, Straubhaar J, Czech MP. Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol. 2011;301(4):H1425–37. https://doi.org/10.1152/ajpheart.00376.2011.CrossRefPubMedPubMedCentral

32.

van Dam AD, Boon MR, Berbee JFP, Rensen PCN, van Harmelen V. Targeting white, brown and perivascular adipose tissue in atherosclerosis development. Eur J Pharmacol. 2017;816:82–92. https://doi.org/10.1016/j.ejphar.2017.03.051.CrossRefPubMed

33.

Shen FM, Su DF. The effect of adenosine on blood pressure variability in sinoaortic denervated rats is mediated by adenosine A2a-receptor. J Cardiovasc Pharmacol. 2000;36(5):681–6.CrossRef

34.

Than A, Xu S, Li R, Leow MS, Sun L, Chen P. Angiotensin type 2 receptor activation promotes browning of white adipose tissue and brown adipogenesis. Signal Transduct Target Ther. 2017;2:17022. https://doi.org/10.1038/sigtrans.2017.22.CrossRefPubMedPubMedCentral

35.

Zou L, Wang W, Liu S, Zhao X, Lyv Y, Du C, et al. Spontaneous hypertension occurs with adipose tissue dysfunction in perilipin-1 null mice. Biochim Biophys Acta. 2016;1862(2):182–91. https://doi.org/10.1016/j.bbadis.2015.10.024.CrossRefPubMed

36.

Asano A, Irie Y, Saito M. Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes. Mol Cell Endocrinol. 2001;174(1–2):71–6.CrossRef

37.

Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res. 2007;74(2–3):100–13. https://doi.org/10.1016/j.mvr.2007.03.004.CrossRefPubMedPubMedCentral

38.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.CrossRef

39.

Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87(2):262–71. https://doi.org/10.1093/cvr/cvq105.CrossRefPubMedPubMedCentral

40.

Bagchi M, Kim LA, Boucher J, Walshe TE, Kahn CR, D'Amore PA. Vascular endothelial growth factor is important for brown adipose tissue development and maintenance. FASEB J. 2013;27(8):3257–71. https://doi.org/10.1096/fj.12-221812.CrossRefPubMedPubMedCentral

41.

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–9.CrossRef

42.

Wang GX, Zhao XY, Lin JD. The brown fat secretome: metabolic functions beyond thermogenesis. Trends Endocrinol Metab. 2015;26(5):231–7. https://doi.org/10.1016/j.tem.2015.03.002.CrossRefPubMedPubMedCentral

43.

Sun K, Kusminski CM, Luby-Phelps K, Spurgin SB, An YA, Wang QA, et al. Brown adipose tissue derived VEGF-A modulates cold tolerance and energy expenditure. Mol Metab. 2014;3(4):474–83. https://doi.org/10.1016/j.molmet.2014.03.010.CrossRefPubMedPubMedCentral

44.

Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30(6):591–601. https://doi.org/10.1016/j.semnephrol.2010.09.007.CrossRefPubMedPubMedCentral

45.

LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension. 2008;51(4):982–8. https://doi.org/10.1161/HYPERTENSIONAHA.107.108837.CrossRefPubMedPubMedCentral

46.

Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008;52(3):452–9. https://doi.org/10.1161/HYPERTENSIONAHA.108.117366.CrossRefPubMed

47.

Tang EH, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther. 2009;122(2):140–9. https://doi.org/10.1016/j.pharmthera.2009.02.006.CrossRefPubMed

48.

Granger JP. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension. 2009;54(3):465–7. https://doi.org/10.1161/HYPERTENSIONAHA.109.132274.CrossRefPubMedPubMedCentral

49.

Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–8. https://doi.org/10.1161/HYPERTENSIONAHA.109.129973.CrossRefPubMedPubMedCentral

50.

Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Phys. 1998;274(3 Pt 2):H1054–8.

51.

Villarroya F, Cereijo R, Villarroya J, Giralt M. Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017;13(1):26–35. https://doi.org/10.1038/nrendo.2016.136.CrossRef

52.

Prisant LM, Gujral JS, Mulloy AL. Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens (Greenwich). 2006;8(8):596–9.CrossRef

53.

Stabouli S, Papakatsika S, Kotsis V. Hypothyroidism and hypertension. Expert Rev Cardiovasc Ther. 2010;8(11):1559–65. https://doi.org/10.1586/erc.10.141.CrossRefPubMed

54.

Bianco AC, McAninch EA. The role of thyroid hormone and brown adipose tissue in energy homoeostasis. Lancet Diabetes Endocrinol. 2013;1(3):250–8. https://doi.org/10.1016/S2213-8587(13)70069-X.CrossRefPubMedPubMedCentral

55.

Silva JE, Larsen PR. Potential of brown adipose tissue type II thyroxine 5′-deiodinase as a local and systemic source of triiodothyronine in rats. J Clin Invest. 1985;76(6):2296–305. https://doi.org/10.1172/JCI112239.CrossRefPubMedPubMedCentral

56.

Cvoro A, Bajic A, Zhang A, Simon M, Golic I, Sieglaff DH, et al. Ligand independent and subtype-selective actions of thyroid hormone receptors in human adipose derived stem cells. PLoS One. 2016;11(10):e0164407. https://doi.org/10.1371/journal.pone.0164407.CrossRefPubMedPubMedCentral

57.

Broeders EP, Vijgen GH, Havekes B, Bouvy ND, Mottaghy FM, Kars M, et al. Thyroid hormone activates Brown adipose tissue and increases non-shivering thermogenesis—a cohort study in a group of thyroid carcinoma patients. PLoS One. 2016;11(1):e0145049. https://doi.org/10.1371/journal.pone.0145049.CrossRefPubMedPubMedCentral

58.

Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 2011;286(15):12983–90. https://doi.org/10.1074/jbc.M110.215889.CrossRefPubMedPubMedCentral

59.

•• Ruan CC, Kong LR, Chen XH, Ma Y, Pan XX, Zhang ZB, et al. A2A receptor activation attenuates hypertensive cardiac remodeling via promoting brown adipose tissue-derived FGF21. Cell Metab. 2018; https://doi.org/10.1016/j.cmet.2018.06.013. This study shows that BAT-secreted FGF21 regulates hypertension. CrossRef

60.

Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. https://doi.org/10.1038/ncomms3019.CrossRefPubMed

61.

Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, et al. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 2013;3:2767. https://doi.org/10.1038/srep02767.CrossRefPubMedPubMedCentral

62.

Kikai M, Yamada H, Wakana N, Terada K, Yamamoto K, Wada N, et al. Adrenergic receptor-mediated activation of FGF-21-adiponectin axis exerts atheroprotective effects in brown adipose tissue-transplanted apoE(−/−) mice. Biochem Biophys Res Commun. 2018;497(4):1097–103. https://doi.org/10.1016/j.bbrc.2018.02.185.CrossRefPubMed

63.

He JL, Zhao M, Xia JJ, Guan J, Liu Y, Wang LQ, et al. FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. Sci Rep. 2016;6:29582. https://doi.org/10.1038/srep29582.CrossRefPubMedPubMedCentral

64.

Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, et al. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol. 2011;75(4):464–9. https://doi.org/10.1111/j.1365-2265.2011.04078.x.CrossRef

65.

Semba RD, Crasto C, Strait J, Sun K, Schaumberg DA, Ferrucci L. Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults. J Hum Hypertens. 2013;27(6):397–9. https://doi.org/10.1038/jhh.2012.52.CrossRefPubMed

66.

Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24(3):435–44. https://doi.org/10.1161/01.ATV.0000105902.89459.09.CrossRefPubMed

67.

•• Cirrik S, Schmid-Schonbein GW. IGF-1 receptor cleavage in hypertension. Hypertens Res. 2018;41(6):406–13. https://doi.org/10.1038/s41440-018-0023-7. This study describes how IGF-1 receptor secretion and cleavage regulate hypertension. CrossRefPubMed

68.

Hasdai D, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension. 1998;32(2):228–34.CrossRef

69.

Pendergrass M, Fazioni E, Collins D, DeFronzo RA. IGF-I increases forearm blood flow without increasing forearm glucose uptake. Am J Phys. 1998;275(2 Pt 1):E345–50.

70.

Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology. 1996;137(5):1798–803. https://doi.org/10.1210/endo.137.5.8612517.CrossRefPubMed

71.

Marczin N, Papapetropoulos A, Catravas JD. Tyrosine kinase inhibitors suppress endotoxin- and IL-1 beta-induced NO synthesis in aortic smooth muscle cells. Am J Phys. 1993;265(3 Pt 2):H1014–8. https://doi.org/10.1152/ajpheart.1993.265.3.H1014.CrossRef

72.

Gunawardana SC, Piston DW. Reversal of type 1 diabetes in mice by brown adipose tissue transplant. Diabetes. 2012;61(3):674–82. https://doi.org/10.2337/db11-0510.CrossRefPubMedPubMedCentral

73.

Gunawardana SC, Piston DW. Insulin-independent reversal of type 1 diabetes in nonobese diabetic mice with brown adipose tissue transplant. Am J Physiol Endocrinol Metab. 2015;308(12):E1043–55. https://doi.org/10.1152/ajpendo.00570.2014.CrossRefPubMedPubMedCentral

74.

Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012;60(3):653–8. https://doi.org/10.1161/HYPERTENSIONAHA.112.197780.CrossRefPubMed

75.

Aldiss P, Davies G, Woods R, Budge H, Sacks HS, Symonds ME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265–74. https://doi.org/10.1016/j.ijcard.2016.11.074.CrossRefPubMedPubMedCentral

76.

Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8. https://doi.org/10.1038/nature10777.CrossRefPubMedPubMedCentral

77.

Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279–91. https://doi.org/10.1016/j.cell.2014.03.065.CrossRefPubMedPubMedCentral

78•.

. Erdem Y, Ozkan G, Ulusoy S, Arici M, Derici U, Sengul S, et al. The effect of intermittent fasting on blood pressure variability in patients with newly diagnosed hypertension or prehypertension. J Am Soc Hypertens. 2018;12(1):42–9. https://doi.org/10.1016/j.jash.2017.11.008. This study shows that intermittent fasting regulates blood pressure. CrossRefPubMed

79.

Rachid TL, Penna-de-Carvalho A, Bringhenti I, Aguila MB, Mandarim-de-Lacerda CA, Souza-Mello V. Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice. Mol Cell Endocrinol. 2015;402:86–94. https://doi.org/10.1016/j.mce.2014.12.027.CrossRefPubMed

80.

Ohno H, Shinoda K, Spiegelman BM, Kajimura S. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 2012;15(3):395–404. https://doi.org/10.1016/j.cmet.2012.01.019.CrossRefPubMedPubMedCentral

81.

Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26(1):172–8.CrossRef

82.

Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens. 2013;31(4):820–9. https://doi.org/10.1097/HJH.0b013e32835e8227.CrossRefPubMedPubMedCentral

83.

Wang Y, He Z, Li X. Chronic rapamycin treatment improved metabolic phenotype but inhibited adipose tissue browning in high-fat diet-fed C57BL/6J mice. Biol Pharm Bull. 2017;40(9):1352–60. https://doi.org/10.1248/bpb.b16-00946.CrossRefPubMed

84.

Tran CM, Mukherjee S, Ye L, Frederick DW, Kissig M, Davis JG, et al. Rapamycin blocks induction of the thermogenic program in white adipose tissue. Diabetes. 2016;65(4):927–41. https://doi.org/10.2337/db15-0502.CrossRefPubMedPubMedCentral

85.

Ma X, Yao J, Yue Y, Du S, Qin H, Hou J, et al. Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model. Interact Cardiovasc Thorac Surg. 2017;25(2):206–11. https://doi.org/10.1093/icvts/ivx053.CrossRefPubMed

86.

Feng RN, Zhao C, Wang C, Niu YC, Li K, Guo FC, et al. BMI is strongly associated with hypertension, and waist circumference is strongly associated with type 2 diabetes and dyslipidemia, in northern Chinese adults. J Epidemiol. 2012;22(4):317–23.CrossRef

87.

Ni J, Ma KL, Wang CX, Liu J, Zhang Y, Lv LL, et al. Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells. Lipids Health Dis. 2013;12:49. https://doi.org/10.1186/1476-511X-12-49.CrossRefPubMedPubMedCentral

88.

Nickenig G, Sachinidis A, Seewald S, Bohm M, Vetter H. Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens Suppl. 1997;15(6):S27–30.CrossRef

89.

Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012;14(2):160–9. https://doi.org/10.1007/s11906-012-0245-z.CrossRefPubMedPubMedCentral

90.

Berbee JF, Boon MR, Khedoe PP, Bartelt A, Schlein C, Worthmann A, et al. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat Commun. 2015;6:6356. https://doi.org/10.1038/ncomms7356.CrossRefPubMedPubMedCentral

91.

• Kishida T, Ejima A, Yamamoto K, Tanaka S, Yamamoto T, Mazda O. Reprogrammed functional Brown adipocytes ameliorate insulin resistance and dyslipidemia in diet-induced obesity and type 2 diabetes. Stem Cell Reports. 2015;5(4):569–81. https://doi.org/10.1016/j.stemcr.2015.08.007. This study describes how brown fat regulates dyslipidemia. CrossRefPubMedPubMedCentral

Title: Adipose Tissue and Modulation of Hypertension
Authors: Eashita Das
Joon Ho Moon
Ju Hee Lee
Nikita Thakkar
Zdenka Pausova
Hoon-Ki Sung
Publication date: 01-11-2018
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 11/2018
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0894-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Adipose Tissue and Modulation of Hypertension

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 11/2018

SPRINT and the Kidney: What Have We Learned?

Skin Sodium and Hypertension: a Paradigm Shift?

Effect of L-Citrulline Supplementation on Blood Pressure: a Systematic Review and Meta-Analysis of Clinical Trials

Chronotherapy for Hypertension

Modulation of Sympathetic Overactivity to Treat Resistant Hypertension

Catheter-Based Renal Denervation for Hypertension

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page